Compare Adaptive Biotechnologies Corp (ADPT) vs Nike Inc (NKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nike Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Nike Inc trades at $42.85 (market cap $63.99B). The key difference: Nike Inc is far larger — about 19.2× Adaptive Biotechnologies Corp's market cap, and Nike Inc pays a 3.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NKE | |
|---|---|---|
Market Cap | $3.33B | $63.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $79.24 |
52-Week Low | $10.24 | $40.75 |
Enterprise Value | $3.19B | $66.00B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Nike (NKE) trades at $43.34, down 1.7% on the day, with a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, but revenue declined to $46.31B in 2025 with net income falling to $3.22B. The stock shows strong profitability margins and a P/E of 20.64, while analysts maintain a consensus Buy rating with a $50.67 price target. Key support lies at $42, with resistance at $44.
Nike faces near-term headwinds from sluggish consumer demand and margin pressure, but its brand strength and digital direct-to-consumer strategy provide long-term upside potential. Risks include inventory challenges and economic sensitivity, yet institutional confidence remains with 48.6% analyst Buy ratings. The upcoming Q4 2026 earnings on June 30, 2026, will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
